Kornimate/medical-research-clean huggingface dataset:
the guidance of thin cross- section of ct in anatomic segmentectomy

Conditions: Segmentectomy; Video- Assisted Thoracoscopic Surgery; Three-dimensional-computed Tomography (3D-CT); Thin Cross- Section of CT

Summary: three-dimensional (3d) simulation of pulmonary vessels and the space between the lesion and adjacent tissues is regarded improving the safety and accuracy of video-assisted thoracoscopic surgery (vats) for segmentectomy for ground glass opacity (ggo) in lung. however, not every thoracic surgeon can handle the technique, in addition, the 3d reconstruction originate from the thin ct scan. actually, the investigators found that, the reading and comprehension of the thin cross- section of ct can guide the accurate anatomic segmentectomy in most situations. the investigators designed a retrospective study to compare the reading of thin cross- section of ct with 3d reconstruction or without 3d reconstruction during the guidance of anatomic segmentectomy.


Eligibility criteria:
inclusion criteria: selection criteria for vats segmentectomy in the present study were as follows: (i) patients with single peripheral ggo lesion considered suspicious for malignancy; (ii) the lesion \<2 cm in diameter and with at least one of the followings: (i) pure adenocarcinoma in situ (ais) histology; (ii) nodule has ≥50% ground-glass appearance on high resolution ct; (iii) radiologic surveillance conforms a long doubling time (≥400 days). exclusion criteria: (i) patients with insufficient cardiopulmonary function; (ii) other contraindication for segmentectomy.
d-serine for posttraumatic stress disorder treatment

Conditions: Posttraumatic Stress Disorder

Summary: the aim of this study is to asses the effects of the nmda receptor full agonist d-serine while used as adjuvant treatment for individuals suffering from chronic posttraumatic stress disorder (ptsd). dysfunction of neurotransmission mediated at nmda receptor plays a cardinal role in the pathophysiology of ptsd and ptsd patients typically suffer from cognitive dysfunctions and avoidance\& depressive symptomatology that may be mediated by nmda receptor function deficits. thus, enhancement of nmda activity by using d-serine may be beneficial in the treatment of ptsd. the study design involves two 6 week periods during which the participants will be randomly assigned to receive treatment with d-serine (\~2g /dy)and placebo. this design allows each participant the opportunity to respond to the experimental treatment.


Eligibility criteria:
inclusion criteria: • chronic ptsd (dsm-iv diagnosis) exclusion criteria: * other psychiatric diagnosis * substance abuse * unstable medical condition
exercise intervention study for early-stage breast cancer patients receiving neoadjuvant therapy.

Conditions: Breast Cancer

Summary: to determine the effects of endurance exercise training on cardiopulmonary fitness in breast cancer patients undergoing neoadjuvant chemotherapy.

given that this is the first study to explore the potential effects of exercise training on exercise capacity, tumor vascularity and response in women undergoing neoadjuvant chemotherapy for operable breast cancer, prior to the initiation of the full investigation, we will conduct a small vanguard study to ensure we can achieve acceptable exercise adherence rates in the absence of dose-limiting toxicities (dlts). specifically, three operable breast cancer patients will be recruited and enrolled as described below and perform exercise training for a minimum of six weeks. if acceptable exercise rates are observed in the absence of severe dlts during this time, we will proceed with the full investigation (recruitment of additional 20 patients) (see figure 2). using a prospective, randomized design, potential participants will be identified and screened for eligibility by an assigned breast protocol nurse (tbd) via medical record review of patients scheduled for their primary neoadjuvant chemotherapy consultation at dccc

Eligibility criteria:
inclusion criteria: * histologically confirmed operable primary breast cancer * age 18 or older * karnofsky performance status greater than 70 * no previous malignancy * absence of significant cardiac disease (left ventricular ejection fraction greater than or equal to 50%) * no hormonal replacement therapy use within the past month * not pregnant * ability to read and understand english * signed written informed consent prior to beginning protocol specific procedures * willing to travel to dumc to exercise three times per week * primary treating oncologist approval

Keywords: exercise intervention breast cancer neo-adjuvant therapy operable breast cancer stage i-ii receiving neo-adjuvant chemotherapy
arterial blood pressure-complexity in septic patients

Conditions: Sepsis

Summary: arterial blood pressure (abp) is regulated by multiple, interconnected feedback loops resulting in a variable and complex time course. according to the "decomplexification theory of illness", disease is characterised by a loss or impaired function of feedback loops resulting in a decreased complexity of the abp-time course and an impaired adaptability of the cardiovascular system. decomplexification of physiologic parameters has been shown to occur in coronary heart disease, parkinson's and hodgkin's disease, and in subarachnoid hemorrhage, but has not been evaluated in sepsis. this study is intended to test the hypothesis that complexity of abp * is lower in cardiac surgery versus non-cardiac surgery septic patients, * decreases as severity of sepsis increases to severe sepsis and septic shock, * is associated with outcome three month after sepsis.


Eligibility criteria:
inclusion criteria: * patients suffering from sepsis, severe sepsis or septic shock exclusion criteria: * pregnancy

Keywords: sepsis arterial blood pressure complexity variability
epidural injection of corticosteroids under usg (eicus)

Conditions: Pain Management

Summary: qualitative and quantitatively evaluate the pain control and incidence of adverse effects in patients undergoing corticosteroid infiltration and local anesthetic through sacral epidural puncture with ultrasound assistance or isolated use of fluoroscopy to aid puncture and location of the sacral epidural space. a group will be submitted to epidural corticosteroid infiltration associated with local anesthetic with the use of fluoroscopy for locating the sacral epidural space, which is currently the gold standard for this technique, while in another location group will be held with the use of ultrasound.

introduction: procedures guided by ultrasound (usg) have advantages over traditional techniques (fluoroscopy) with respect to regional anesthesia. some studies have shown its usefulness as a quick, safe and simple tool for the location of the sacral hiatus and to guide the puncture of the sacral epidural space in patients with chronic low back pain, despite the lack of data with respect to clinical outcomes. objectives: evaluate qualitatively and quantitatively the pain control and incidence of adverse effects in patients undergoing corticosteroid infiltration and local anesthetic through sacral epidural puncture with ultrasound assistance or isolated use of fluoroscopy to aid puncture and location of the sacral epidural space. it will also be evaluated success rate in the first puncture, and the time duration of the procedure in groups. methods: it is clinical, analytical, prospective trial, randomized, covered for evaluators. it will include 30 patients with chronic low back pain or pain in the lower limbs resulting in lumbar canal stenosis, refractory to medical treatment. a group will be submitted to epidural corticosteroid infiltration associated with local anesthetic with the use of fluoroscopy for locating the sacral epidural space, which is currently the gold standard for this technique, while in another location group will be held with the use of ultrasound.

Eligibility criteria:
inclusion criteria: * older than 18 years old; * patients who have low back and/or lower extremities due to lumbar spinal stenosis pain outpatients, with regular follow-up refractory to conservative medical treatment (verbal scale of pain \> 3, more three months duration, with no improvement with clinical treatment). exclusion criteria: * symptoms that characterize a surgical emergency; * the presence of sensory or motor deficit (chronic mild motor impairment or mild paresthesia will not be deleted), injury to peripheral nerves, trauma history or recent fracture; * serious medical conditions or decompensated; * infection at the puncture site; * coagulopathy; * contrast allergy history or the medications used in the technique; * pregnancy.

Keywords: pain epidural ultrasound
effectiveness of 3,4-diaminopyridine in lambert-eaton myasthenic syndrome

Conditions: Lambert-Eaton Myasthenic Syndrome; Eaton-Lambert Myasthenic Syndrome

Summary: hypothesis: 3,4-diaminopyridine base (3,4-dap) improves lambert-eaton myasthenic syndrome (lems)-related weakness.

the objectives of the study were to confirm the safety and to test the efficacy of 3,4-dap in the treatment of lems-related weakness. this was a phase 2 randomized double-blind placebo-controlled withdrawal study in subjects with known clinically active lems who had been on a chronic stable dose of compassionate distribution jacobus 3,4-dap provided through fda-approved individual investigator-held inds.

Eligibility criteria:
inclusion criteria: 1. age 18 or over 2. ambulatory while taking 3,4-dap, i.e. the patient was able to perform the timed up and go (tug), either with or without an assistive device 3. established diagnosis of lems, with documentation provided 4. continuous use of jacobus 3,4-dap for at least 3 months 5. minimum of 3 doses per day with no single dose less than 10 mg of 3,4-dap 6. the patient needed to wait about 15 to 30 minutes to experience an unequivocal improvement in a lems-induced dysfunction after they take their first dose of 3,4-dap in the morning \[a patient who remains in bed past this point by choice may still be eligible\] 7. stable regimen of all lems-related treatments for at least 3 months 8. stable daily regimen of other medications (prescription and over-the-counter) for a minimum of 1 month 9. willing to chance being tapered off of 3,4-dap 10. fluency in english 11. if applicable, agreed to use birth control during heterosexual intercourse until at least 2 weeks after completion of study 12. a signed informed consent by the study subject exclusion criteria: 1. last monoclonal antibody treatment (e.g. rituximab) was less than 6 months ago (i.e., recent treatment is an exclusion) 2. clinically significant or poorly controlled condition that in the opinion of the study personnel might pose an unacceptable risk to the patient if entered into the study 3. respiratory failure requiring intubation while on 3,4-dap with no precipitating event or medication 4. use of any investigational drug other than 3,4-dap within the last 30 days 5. pregnant or lactating 6. current use of other aminopyridines (e.g.4-ap) or guanidine 7. did not display a sufficiently large response to 3,4-dap during the baseline observation period in the cru to detect a decline during withdrawal of 3,4-dap

Keywords: lambert-eaton eaton-lambert myasthenia myasthenic lems les dap diaminopyridine 3,4-diaminopyridine 3,4-dap
the bear therapeutic program for women

Conditions: Trauma, Psychological; Depression, Anxiety; PTSD

Summary: the current study aims to test a novel therapeutic intervention for women who have a history of interpersonal trauma. the building empowerment and resilience (bear) therapeutic group incorporates psychological skills, psychoeducation, and physical empowerment training, all within a therapeutic process. it will be implemented iwith women who have experienced interpersonal trauma (physical, sexual, or emotional abuse/neglect). the investigators aim to understand how this program effects one's self-efficacy and whether the program can reduce rates mental health problems (such as depression and anxiety) and reduce the rates of revictimization. women who participate in the bear group must be able to attend in-person sessions. the control group can be remote.


Eligibility criteria:
inclusion criteria: 1. women ages 18-70 2. history of physical, sexual, and/or emotional abuse/neglect/violence, with subsequent interpersonal or psychological distress (e.g., depression or anxiety) related to this history. exclusion criteria: 1. active, significant substance abuse 2. significant medical conditions that would preclude safe participation in the study 3. high levels of depression with significant suicide risk 4. psychiatric instability 5. history of assaultive behavior or is judged to be at potential risk to assault others.

Keywords: empowerment therapeutic intervention
covid-19 self-testing study

Conditions: COVID-19

Summary: the goal of this clinical trial is to understand how the introduction of an app-based intervention changes knowledge, attitudes, and practices on covid-19 self-testing.

rapid diagnostic testing has been shown to be an important tool in controlling the spread of the covid-19 pandemic by identifying people when they are likely to be most contagious and reducing crowding at testing sites. in addition to employer-mandated testing, rapid antigen tests are becoming increasingly used by individuals. a method to promote frequent self-testing would help break the chain of viral transmission, slow the spread of disease, slow the spread of vaccine-resistant variants, and improve pandemic management. the ubiquity of smartphones along with their data connectivity capabilities and onboard sensors make them an attractive tool to complement rapid diagnostic tests and an important component of decentralized testing. smartphone-based tools have shown high acceptability among healthcare workers for the real-time tracking of rapid test results.

Eligibility criteria:
inclusion criteria: * english-speaking * 18 years old or older * owns a smartphone running either android or ios operating systems * willing to download a covid-19 self-testing app * willing to receive and send text messages for the study (and fill out surveys linked from text messages) exclusion criteria: * not willing to self-test themselves with covid-19 rapid tests

Keywords: covid-19 self-testing mobile-app smartest randomized control trial rct antigen test mobile health digital health
purpose in life survey

Conditions: Breast Cancer; Traumatic Brain Injury

Summary: at present, there is no empirical data that specifies the likely prevalence of purpose in life disruption among various clinical populations. between one-third and one-half of cancer survivors report some degree of existential distress during or after their treatment, but these findings are not specific to the domain of purpose in life. to address the aforementioned gap, we propose to conduct a survey study to determine the prevalence of purpose disruption in two clinical populations and determine if the prevalence of purpose disruption in these populations is different from that of a normative population.


Eligibility criteria:
inclusion criteria: * age 18+ * stage 1, 2, 3 cancer * cancer types: breast cancer, non-hodgkin's lymphoma; colorectal cancer * receiving oncology services or treatment through ahci * have completed primary cancer treatment within the past 12 months * able to communicate in english; * able to see and read (with or without assistive devices); * has access to a device (computer, phone, tablet) and an email address; * access to an internet connection. * has a known email address (in epic) and/or home telephone number * adults who sustained a traumatic brain injury within the past 12 months. * attending the 2022 mn state fair exclusion criteria: * have declined consent for use of medical records in research during admission to ah facility
bolster: learning new skills to thrive

Conditions: Gastrointestinal Cancer; Gynecologic Cancer; Advanced Cancer

Summary: this research study is evaluating a new program called building out lifelines for safety, trust, empowerment, and renewal or (bolster), which was designed to support participants with a gynecological or gastrointestinal cancer and new and complex care needs.

this multi-center, randomized trial is to test the efficacy of the bolster program and to improve participant quality of life (qol), alleviate symptoms, reduce burden, and decrease the need for hospital care in participants with complex care needs from advanced gastrointestinal and gynecologic (gi/gyn) cancers. the research study procedures include screening for eligibility, questionnaires, and telehealth visits. participation in this research study is expected to last about 12 weeks. about 300 dyads (patients with family caregivers) are expected to participate in this research study. the national cancer institute is funding this research study by providing funding.

Eligibility criteria:
participant inclusion criteria: * age ≥18 years * currently hospitalized with skilled care need or have acquired a new skilled care need as an outpatient * diagnosed with advanced gastrointestinal cancer (esophageal, gastric, pancreatic, hepatobiliary, colorectal, unknown gi primary, anal) or advanced gynecologic cancer (ovarian, endometrial, cervical, vaginal, vulvar) * has a complex care need (e.g., ostomy, ileostomy, urostomy, nephrostomy, biliary drain, venting gastric tube, feeding tube, intraabdominal or pleural catheter, wound vac) * plans to receive ongoing cancer treatment * has a family caregiver or friend (hereafter designated family caregiver) willing to participate * able to speak and read english or spanish (self-report) * are willing to be audio-recorded * have the cognitive/physical ability to participate in a 60-minute interview family or caregiver inclusion criteria: * age ≥ 18 years * identified by a patient (as defined above) as a family or friend who is involved in their care. * willing to participate in study visits * willing to be audio recorded participant exclusion criteria: * has cognitive impairments (as determined by the patient's oncologist) * planning to enroll in hospice * unable to complete baseline survey * adults unable to consent * individuals who are not yet adults (infants, children, teenagers) * prisoners family or caregiver exclusion criteria: * unable to complete baseline survey * adults unable to consent * individuals who are not yet adults (infants, children, teenagers) * prisoners

Keywords: gastrointestinal cancer gynecologic cancer advanced cancer advanced gastrointestinal cancer advanced gynecologic cancer
transversus abdominis plane block and quadratus lumborum block in pediatric patients

Conditions: Pain, Postoperative

Summary: in the pediatric age group, postoperative pain is very important for the children to have a comfortable and problem-free postoperative period. in the present study, it was aimed to compare the postoperative analgesic efficacy of transversus abdominis plane (tap) block, and quadratus lumborum block (qlb) type 1 on the pediatric patients

patients included in the study were randomly divided into 2 groups. cases were assessed ultrasonography-guided tap block (group b, n=20) or ultrasonography-guided ql block. total analgesic amounts in 24 hours and first analgesic requirement times recorded.

Eligibility criteria:
inclusion criteria: * the study included 40 cases undergoing lower abdominal surgery aged from 3 to 16 years with american society of anesthesiologist i-ii level. exclusion criteria: * cases with american society of anesthesiologist iii-iv health level and those with a history of allergy to local anesthetic medications were not included in the study

Keywords: quadratus lumborum block pediatric anesthesia transverse abdominal block
carbon dioxide (co2) and cognitive impairment

Conditions: Healthy

Summary: the purpose of the study is to better understand the biological mechanisms of carbon dioxide (co2)-induced cognitive impairments.

participants will complete 2 study visits. each study visit will consist of a 2.5-hour exposure session. concentrations of co2 during the exposure session will be either 600 ppm (control) or 2500 ppm (exposure). the order of the exposure sessions will be randomized and the exposure sessions will be at least one week apart. up to two participants will take part in each exposure session. during each exposure a neurobehavioral assessment (strategic management simulations or sms) will be administered. venous blood (30 ml) will be collected from subjects immediately before entering the chamber and immediately after the exposure. a subset of subjects (n=12) will also undergo a 60-minute fmri scan. another subset of subjects (up to 10) will not complete the sms during the exposures but will undergo computer-assisted intravital microscopy (caim) to exam the conjunctival microvasculature before and after the exposure.

Eligibility criteria:
inclusion criteria: * history of covid-19 vaccination * weigh at least 110 pounds exclusion criteria: * colorblindness * inability to hear verbal instructions * cardiovascular disease, including a history of stroke * diabetes requiring the use of insulin * pregnancy * current asthma (an asthma attack within the past five years) * medications for or history of anxiety disorder diagnosis or panic attacks * medications which may affect cognition such as beta-blockers and cns depressants temporary exclusion criteria * respiratory symptoms in the previous four weeks * use of sedating cold/allergy medications in the previous week * use of marijuana in the previous week * consumption of alcohol in the previous 24 hours additional exclusion criteria for subjects undergoing the fmri scan: * history of head trauma or neurosurgery or neurological disorder * ferrous metal implanted in or on the body, electrical devices such as a pacemaker, nonremovable ferrous jewelry * surgical pins or plates above the neck * history of eye injury involving metallic materials, shavings in eyes, or welding without a face mask * lead or iron tatoos * claustrophobia * back problems that would prevent the subject from laying still comfortably for up to 90 minutes additional exclusion criteria for subjects undergoing caim * current or recent contact lens use

Keywords: carbon dioxide cognitive impairment
pediatric catheter-related thrombosis imaging study

Conditions: Thrombosis

Summary: this protocol will serve as a pilot study to determine the validity and feasibility of contrast enhanced magnetic resonance imaging (mri) without and with contrast and/or ultrasound (us) for detection of catheter related deep vein thrombosis (dvt) in children


Eligibility criteria:
inclusion criteria: * functioning central venous catheter in the upper or lower venous system * cohort a: asymptomatic patients having placement of a new central venous catheter in the last 40±20 days * cohort b: subjects who have experienced symptoms for a cvc-related dvt with a cvc in place or subjects who have been incidentally identified by radiographic imaging (imaging modalities to diagnose an incidental cvc-related dvt may include, but is not exclusive of echocardiogram, ct scan, mri, or ultrasound) performed for other clinical reasons, as having a cvc-related dvt in the veins where the current catheter is placed * males and females from full-term newborns to \< 18 years exclusion criteria: * for cohort a subjects only, present therapeutic dosing of a systematic anticoagulant, systemic thromboprophylaxis or antiplatelet therapy. local thromboprophylaxis \[flushes, low dose infusions of heparin of up to 5 u/kg/hr or locks with heparin, urokinase, t-plasminogen activator\] according to standard-of-care at the respective center will be allowed * patients unable to undergo contrast enhanced magnetic resonance imaging * renal function \< 50% of normal for age and size